Form 3: Denali insider Stephen Ma reports 2.5M stock option with exercisability limits
Rhea-AI Filing Summary
Stephen Ma, Chief Financial Officer, Senior Vice President and Secretary of Semnur Pharmaceuticals, filed an initial Form 3 reporting a direct stock option to buy 2,500,000 shares of Denali Capital Acquisition Corp. (ticker shown as SMNR in the filing). The option has a $1.27 exercise price and a term expiring 08/30/2034. The option vests monthly (1/48th per month) and became exercisable in connection with the completed business combination and option exchange approved by shareholders, but exercisability and attendant rights are suspended while a Senior Secured Promissory Note issued by Scilex Holding Company to Oramed Pharmaceuticals remains unpaid. The filing identifies the reporting person’s officer role and includes a signed power of attorney.
Positive
- Transparent disclosure of insider ownership and option terms filed promptly on Form 3
- Material option size (2,500,000 shares) disclosed, allowing investors to model potential dilution
- Clear vesting schedule (1/48th monthly) provides predictable timeline for future exercisability absent restrictions
Negative
- Exercisability and rights are suspended until a Senior Secured Promissory Note is paid in full, limiting immediate shareholder impact
- Contingent dilution risk exists because the option could convert into common shares if conditions are met
- Link to controlling stockholder indebtedness (Scilex Holding Company’s note to Oramed) creates uncertainty about timing and triggers
Insights
TL;DR: Large option grant disclosed; exercisability constrained by outstanding debt tied to a controlling stockholder.
The filing reports a substantial 2.5 million-share option with a low exercise price of $1.27, which could meaningfully dilute equity upon exercise if converted into common stock. Vesting is scheduled monthly (1/48th), so economic exposure will accumulate steadily. However, explicit suspension of exercisability, voting rights and dividend participation until the referenced promissory note is paid in full materially limits near-term conversion and shareholder influence. For valuation or ownership analyses, treat the option as contingent until the debt condition is resolved.
TL;DR: Transparent Section 16 disclosure of insider option; governance impact muted by contractual restrictions tied to third-party note.
The Form 3 provides clear disclosure of the reporting person’s officer role and a direct option position. Crucially, the filing states that until the senior secured promissory note is paid in full, the option lacks exercisability, voting rights and dividend participation. That limitation reduces immediate governance risk from this insider’s position but creates a contingent governance interest that could activate if the note is satisfied. Investors should note the linkage between a controlling stockholder’s indebtedness and potential future shifts in ownership and control.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Footnotes (1)
- The option vests in equal monthly installments of 1/48th per month. Except as described in the next sentence, the option is currently exercisable pursuant to the approval by shareholders of the Issuer of the option exchange on September 3, 2025, as described in the Issuer's Registration Statement on Form S-4 filed with the Securities and Exchange Commission (File No. 333-283019), which became effective on August 12, 2025. Until the date on which all payments and all obligations under that certain Senior Secured Promissory Note, dated as of September 21, 2023, issued by Scilex Holding Company (the controlling stockholder of the Issuer) to Oramed Pharmaceuticals, Inc., a Delaware corporation, (Continued from footnote 1) have been paid in full in cash, the options will not be or become exercisable, eligible for exchange, redemption or repurchase, eligible to participate in any dividends or distributions (including the proceeds of any corporate transaction) or have any voting rights in respect of, among other things, the Issuer or any of its respective current and future subsidiaries, successors and assigns. The option expires ten years from the date of issuance, unless earlier terminated in accordance with the terms of the Semnur Pharmaceuticals, Inc. 2024 Stock Option Plan. Represents shares of the Issuer's Common Stock underlying the option, for which (except as described above) the option became exercisable in connection with a business combination (the "Business Combination") which was effectuated in accordance with the terms of the Agreement and Plan of Merger, dated as of August 30, 2024 (as amended on April 16, 2025 and July 22, 2025), by and among the Issuer, a wholly owned subsidiary of the Issuer, and Semnur, Inc. (f/k/a Semnur Pharmaceuticals, Inc.) ("Old Semnur"), which became a wholly owned subsidiary of the Issuer upon completion of the Business Combination. Upon consummation of the Business Combination, the reporting person's option to purchase shares of common stock of Old Semnur was exchanged for an option to purchase shares of common stock of the Issuer at an exchange ratio of 1.25 to 1. The number of shares reflects the application of the exchange ratio.
